Universe Pharmaceuticals INC (UPC)
NASDAQ: UPC · Real-Time Price · USD
3.800
-0.010 (-0.26%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China.

It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.

Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China.

Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC
Universe Pharmaceuticals INC logo
Country China
Founded 1998
IPO Date Mar 23, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 225
CEO Gang Lai

Contact Details

Address:
265, Jingjiu Avenue, Jinggangshan Eco & Tech Dev Zn
Ji'An, 343100
China
Phone 86 79 6840 3309
Website universe-pharmacy.com

Stock Details

Ticker Symbol UPC
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
IPO Price $5.00
CIK Code 0001809616
CUSIP Number G9442G104
ISIN Number KYG9442G1120
SIC Code 2834

Key Executives

Name Position
Gang Lai Chief Executive Officer and Chairman
Lin Yang Chief Financial Officer and Director
Baochang Liu Chief Operating Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 6-K Report of foreign issuer
Mar 11, 2025 6-K Report of foreign issuer
Mar 3, 2025 6-K Report of foreign issuer
Feb 25, 2025 6-K Report of foreign issuer
Feb 20, 2025 6-K Report of foreign issuer
Feb 18, 2025 6-K Report of foreign issuer
Feb 14, 2025 SCHEDULE 13G Filing
Feb 11, 2025 6-K Report of foreign issuer
Feb 3, 2025 6-K Report of foreign issuer
Jan 30, 2025 6-K Report of foreign issuer